1 Recommendations

dMMR endometrial cancer

1.1

Durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, can be used as an option for untreated primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) in adults who can have systemic treatment. It can only be used if the company provides it according to the commercial arrangement.

1.2

Durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, should be stopped after 3 years, or earlier if there is disease progression or unacceptable toxicity.

pMMR endometrial cancer

1.3

Durvalumab with platinum-based chemotherapy, then maintenance durvalumab plus olaparib, should not be used for untreated primary advanced or recurrent endometrial cancer that is mismatch repair proficient (pMMR) in adults who can have systemic treatment.

About these recommendations

1.4

These recommendations are not intended to affect treatment with durvalumab with platinum-based chemotherapy, then maintenance durvalumab with or without olaparib, that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.

What this means in practice

dMMR endometrial cancer

Durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, must be funded in the NHS in England for untreated primary advanced or recurrent endometrial cancer that is dMMR in adults who can have systemic treatment, if it is considered the most suitable treatment option. It should be stopped after 3 years, or earlier if there is disease progression or unacceptable toxicity.

Early funding for durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, is available through the Cancer Drugs Fund from the point of marketing authorisation or release of positive draft guidance, whichever is later. Funding is available until 90 days after final publication of this guidance. After that, durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy, must be funded through routine commissioning in England.

There is enough evidence to show that durvalumab with platinum-based chemotherapy, then maintenance durvalumab monotherapy provides benefits and value for money in adults whose cancer is dMMR, so it can be used routinely across the NHS in this population.

pMMR endometrial cancer

Durvalumab with platinum-based chemotherapy, then maintenance durvalumab plus olaparib, is not required to be funded in the NHS in England for untreated primary advanced or recurrent endometrial cancer that is pMMR in adults who can have systemic treatment. It should not be used routinely in the NHS in England in this population.

This is because the available evidence does not suggest that durvalumab with platinum-based chemotherapy, then maintenance durvalumab plus olaparib, offers value for money in adults whose endometrial cancer is pMMR.

NICE has produced tools and resources to support the implementation of this guidance.

Why the committee made these recommendations

Endometrial cancer can be dMMR or pMMR based on how well endometrial cells can correct mutations in DNA. Usual treatment for untreated primary advanced or recurrent endometrial cancer is platinum-based chemotherapy (from here, just chemotherapy) then routine surveillance.

dMMR endometrial cancer

Clinical trial evidence shows that durvalumab with chemotherapy then maintenance durvalumab alone (monotherapy) gives people longer before their condition gets worse than just chemotherapy then routine surveillance. Evidence suggests that it also increases how long people live, but this is uncertain because the study is ongoing and has only followed people for a short time.

The cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So durvalumab with chemotherapy then maintenance durvalumab alone can be used for endometrial cancer that is dMMR.

Durvalumab should be stopped after 3 years, or earlier if the condition gets worse or there are unacceptable side effects. This reflects how other immunotherapies like durvalumab are used in clinical practice, and how clinical experts said they would use durvalumab.

pMMR endometrial cancer

Clinical trial evidence shows that durvalumab with chemotherapy, then maintenance durvalumab plus olaparib, gives people longer before their condition gets worse than just chemotherapy then routine surveillance. Evidence suggests that it also increases how long people live, but this is uncertain because the study is ongoing and has only followed people for a short time.

The cost-effectiveness estimates are substantially above the range that NICE considers an acceptable use of NHS resources. So durvalumab with platinum-based chemotherapy then maintenance durvalumab plus olaparib should not be used for endometrial cancer that is pMMR.